- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
IOL range expands
An IOL (Softec HD, Lenstec) for treating cataracts now is available in an expanded range of prescriptions, covering 15.0 to 25.0 D. Since its approval by the FDA in April 2010, it had been available in mid-range powers between 18.0 and 25.0 D.
St. Petersburg, FL-An IOL (Softec HD, Lenstec) for treating cataracts now is available in an expanded range of prescriptions, covering 15 to 25 D. Since its approval by the FDA in April 2010, it had been available in mid-range powers between 18 and 25 D.
The bi-aspheric IOL has a stable uniplanar design and is manufactured to a tolerance of ±0.11 D, making it the most predictable IOL on the U.S. market, according to the company, which notes that the industry standard 0.40-D tolerance is set in accordance with less-stringent ISO guidelines.
The company’s proprietary manufacturing process is designed to reduce variability and produce the IOL in non-overlapping 0.25-D increments throughout its full 15- to 25-D range. In contrast, most IOLs are manufactured in 0.50-D increments that may overlap, according to the company.
